June 11, 2012

Sanofi Announces Results of ORIGIN, the World’s Longest and Largest Randomized Clinical Trial in Pre- and Early Diabetes

 

Sanofi Announces Results of ORIGIN, the World’s Longest and Largest Randomized Clinical Trial in Pre- and Early Diabetes

Paris, France – June 11, 2012 – Sanofi (EURONEXT: SAN and NYSE: SNY) announced today results from the landmark ORIGIN trial (Outcome Reduction with Initial Glargine Intervention), which showed that Lantus® (insulin glargine [rDNA] injection) had no statistically significant positive or negative impact on cardiovascular (CV) outcomes versus standard care during the study period. Results also showed that insulin glargine delayed progression from pre-diabetes to type 2 diabetes and there was no association between insulin glargine use and increased risk of any cancer. The study findings were presented today at the American Diabetes Association 72nd Scientific Sessions and also published online in the New England Journal of Medicine (NEJM).